The Prostate

Cover image for The Prostate

1 November 2004

Volume 61, Issue 3

Pages 201–297

  1. Research Articles

    1. Top of page
    2. Research Articles
    3. Research Articles
    1. Trefoil factor 3 is overexpressed in human prostate cancer (pages 209–214)

      Isla P. Garraway, David Seligson, Jonathan Said, Steve Horvath and Robert E. Reiter

      Version of Record online: 15 APR 2004 | DOI: 10.1002/pros.20096

    2. Trefoil factor 3 overexpression in prostatic carcinoma: Prognostic importance using tissue microarrays (pages 215–227)

      Dennis A. Faith, William B. Isaacs, James D. Morgan, Helen L. Fedor, Jessica L. Hicks, Leslie A. Mangold, Patrick C. Walsh, Alan W. Partin, Elizabeth A. Platz, Jun Luo and Angelo M. De Marzo

      Version of Record online: 15 APR 2004 | DOI: 10.1002/pros.20095

    3. CVS-3983, a selective matriptase inhibitor, suppresses the growth of androgen independent prostate tumor xenografts (pages 228–235)

      Anna V. Galkin, Lynne Mullen, William D. Fox, Jason Brown, David Duncan, Ofir Moreno, Edwin L. Madison and David B. Agus

      Version of Record online: 15 APR 2004 | DOI: 10.1002/pros.20094

    4. Restoration of fibroblast growth factor receptor2 suppresses growth and tumorigenicity of malignant human prostate carcinoma PC-3 cells (pages 236–242)

      Hiroaki Yasumoto, Akio Matsubara, Kazuaki Mutaguchi, Tsuguru Usui and Wallace L. McKeehan

      Version of Record online: 15 APR 2004 | DOI: 10.1002/pros.20093

  2. Research Articles

    1. Top of page
    2. Research Articles
    3. Research Articles
    1. Epothilone induced cytotoxicity is dependent on p53 status in prostate cells (pages 243–247)

      Margarita L. Ioffe, Eileen White, Deirdre A. Nelson, D. Dvorzhinski and Robert S. DiPaola

      Version of Record online: 22 APR 2004 | DOI: 10.1002/pros.20108

    2. HPC2/ELAC2 polymorphism associated with Japanese sporadic prostate cancer (pages 248–252)

      Akira Yokomizo, Hirofumi Koga, Naoko Kinukawa, Taiji Tsukamoto, Yoshihiko Hirao, Hideyuki Akaza, Mitsuru Mori and Seiji Naito

      Version of Record online: 22 APR 2004 | DOI: 10.1002/pros.20107

    3. Inhibitory effect of IL-6-induced neuroendocrine cells on prostate cancer cell proliferation (pages 253–259)

      Qingcai Wang, Dimitris Horiatis and Jacek Pinski

      Version of Record online: 22 APR 2004 | DOI: 10.1002/pros.20106

    4. Lesions predictive for prostate cancer in a screened population: First and second screening round findings (pages 260–266)

      Renske Postma, Monique Roobol, Fritz H. Schröder and Theodorus H. van der Kwast

      Version of Record online: 22 APR 2004 | DOI: 10.1002/pros.20105

    5. Vitamin D receptor gene polymorphisms and disease free survival after radical prostatectomy (pages 267–275)

      Heinric Williams, Isaac J. Powell, Susan J. Land, Wael A. Sakr, Mark R. Hughes, Nimesh P. Patel, Lance K. Heilbrun and Richard B. Everson

      Version of Record online: 22 APR 2004 | DOI: 10.1002/pros.20103

    6. Androgen receptor (AR) expression in AR-negative prostate cancer cells results in differential effects of DHT and IGF-I on proliferation and AR activity between localized and metastatic tumors (pages 276–290)

      Stephen R. Plymate, Marie K. Tennant, Stephen H. Culp, Lillie Woodke, Marco Marcelli, Ilsa Colman, Peter S. Nelson, Julie M. Carroll, Charles T. Roberts Jr. and Joy L. Ware

      Version of Record online: 22 APR 2004 | DOI: 10.1002/pros.20099

    7. Prostasomes are secreted from poorly differentiated cells of prostate cancer metastases (pages 291–297)

      Göran Sahlén, Anders Ahlander, Anders Frost, Gunnar Ronquist, Bo Johan Norlén and B. Ove Nilsson

      Version of Record online: 22 APR 2004 | DOI: 10.1002/pros.20090

SEARCH

SEARCH BY CITATION